ABK Biomedical and MURR partner to advance breakthrough cancer treatments
The partnership will combine ABK's pioneering device technology with MURR's proven capabilities in isotope production and research excellence
3 Apr 2026
ABK Biomedical and the University of Missouri Research Reactor (MURR) are powering the next generation of cancer treatment. The two partners have signed a long-term agreement naming MURR as the primary irradiation partner for Eye90 microspheres®, an advanced Yttrium-90 (Y-90) radioembolization therapy designed to fight liver cancer.
This strategic partnership builds on seven years of collaboration between ABK and MURR, a relationship that has already driven critical progress in Eye90 development and is fueling the recently-fully-enrolled Route90 FDA IDE clinical trial for hepatocellular carcinoma (HCC).
By formalizing this continuing alliance, ABK secures a reliable and scalable production partner for Eye90 microspheres and brings life-saving treatments closer to patients worldwide.
The agreement also reflects a shared vision for advancing medical innovation. Together, ABK and MURR are creating a foundation for global access to novel cancer therapies, combining ABK's pioneering device technology with MURR's proven capabilities in isotope production and research excellence.
University of Missouri President, Mun Choi said, "Our partnership with ABK Biomedical strengthens Missouri's role as a national leader in medical innovation and delivers direct benefits to patients and communities across the state. This kind of collaboration accelerates discovery and improves lives here at home and around the world."
Mike Mangano, President and CEO of ABK Biomedical, added, "MURR is internationally recognized for its leadership in nuclear research and medical isotope production. This agreement marks a major milestone as we transition from clinical development to commercialization. It underscores our commitment to Columbia, Missouri, and our confidence in MURR's unmatched expertise."